You are here

  • Home
  • Archive
  • Volume 12, Issue 5
  • Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation

Authors

  • Tamara Gassner Department of Basic and Translational Oncology and Hematology, Division of Molecular Oncology and Hematology, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Christina Chittilappilly Department of Basic and Translational Oncology and Hematology, Division of Molecular Oncology and Hematology, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Theo Pirich Department of Basic and Translational Oncology and Hematology, Division of Molecular Oncology and Hematology, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Benjamin Neuditschko Institute Krems Bioanalytics, IMC University of Applied Sciences, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Klaus Hackner Karl Landsteiner University of Health Sciences, Krems an der Donau, AustriaDivision of Pneumology, University Hospital Krems, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Judith Lind Department of Basic and Translational Oncology and Hematology, Division of Molecular Oncology and Hematology, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Osman Aksoy Department of Basic and Translational Oncology and Hematology, Division of Molecular Oncology and Hematology, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Uwe Graichen Department of General Health Studies, Division Biostatistics and Data Sciences, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Sascha Klee Department of General Health Studies, Division Biostatistics and Data Sciences, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Franz Herzog Institute Krems Bioanalytics, IMC University of Applied Sciences, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Christoph Wiesner Department of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Peter Errhalt Karl Landsteiner University of Health Sciences, Krems an der Donau, AustriaDivision of Pneumology, University Hospital Krems, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Martin Pecherstorfer Division of Internal Medicine 2, University Hospital Krems, Krems an der Donau, AustriaKarl Landsteiner Institute of Supportive Cancer Therapy, Karl Landsteiner Gesellschaft, St. Poelten, Austria PubMed articlesGoogle scholar articles
  • Klaus Podar Department of Basic and Translational Oncology and Hematology, Division of Molecular Oncology and Hematology, Karl Landsteiner University of Health Sciences, Krems an der Donau, AustriaDivision of Internal Medicine 2, University Hospital Krems, Krems an der Donau, Austria PubMed articlesGoogle scholar articles
  • Sonia Vallet Department of Basic and Translational Oncology and Hematology, Division of Molecular Oncology and Hematology, Karl Landsteiner University of Health Sciences, Krems an der Donau, AustriaDivision of Internal Medicine 2, University Hospital Krems, Krems an der Donau, AustriaKarl Landsteiner Institute of Supportive Cancer Therapy, Karl Landsteiner Gesellschaft, St. Poelten, Austria PubMed articlesGoogle scholar articles

Citation

Gassner T, Chittilappilly C, Pirich T, et al
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation
Journal for ImmunoTherapy of Cancer 2024;12:e008669. doi: 10.1136/jitc-2023-008669
Online issue publication 
May 03, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.